Trial Details
Not RecruitingBasic Information
| Clinical ID | c5449 |
|---|---|
| Identifier | ACTRN12620000910909 |
| Trial Title | A Phase I, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses of RS1805 Tablets in Healthy Adult Subjects |
| Trial URL | Visit Original Page |
Study Information
| Study Results | Yes |
|---|---|
| Conditions | Inflammatory Bowel Disease; Inflammatory Bowel Disease;Oral and Gastrointestinal - Inflammatory bowel disease |
| Interventions | Part 1 (Single Ascending Dose)Lowest starting dose of 50 mg RS1805 tablets, and the dose level will be gradually escalated. The maximum dose in the single ascending-dose part is planned to be 600 mg RS1805 tablets administered orally. The intervention |
Participant Information
| Sponsor | Atridia Pty Ltd |
|---|---|
| City | NULL |
| Country/Region | Australia;China |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE1 |
Time Information
| Start Date | NULL |
|---|---|
| Primary Completion Date | NULL |
| Completion Date | NULL |